. Serum from patient AH was found to react with a cell surface antigen expressed by cultured autologous melanoma cells, but not by autologous skin fibroblasts or peripheral blood lymphocytes. Absorption tests indicated that AH antigen was expressed by some allogeneic melanoma cell lines, but not by any other normal or malignant cell types examined (1). An antigen with related properties was found during a comparable study of the autologous reactivity of sera from patients with astrocytoma (2). This antigen, A J, was expressed by all astrocytoma cell lines and a high proportion of melanoma cell lines, but was not detected on cultured fibroblasts or epithelial cancers. Comparison of the AJ and AH phenotypes of a series of melanoma cell lines showed only two phenotypes, AJ+/AH + or AJ-/AH-, suggesting a serological relatedness of AH and AJ antigens. Of the 75 patients with melanoma that have been analyzed for autologous reactivity, <5% have had demonstrable AH antibody in their sera (3). Overt cancer is not a prerequisite for the presence of AH antibody, because sera from 6 of 106 normal individuals were also found to have AH reactivity (4). In the present report, we summarize the results of typing an extensive panel of human cell types for AH antigen and provide evidence that the AH determinant is related to GD2 ~ ganglioside.
fraction by Florisil and DEAE-Sephadex chromatography (see ref. 7) . Individual gangliosides were isolated by silica gel chromatography. The sample (1 ml) was applied to a column (60 × 1 cm) of Iatrobeads (Iatron Chemical Co., Tokyo, Japan) equilibrated in n-propanol: NH4OH:H20, (60:9.5:11.5) (solvent 1). Gangliosides were eluted with the same solvent, and 400-pl fractions were collected after discarding the first 10 ml of the eluate. Gangliosides were detected by applying aliquots of the fractions to an activated silica gel plate (Rediplates; Fisher Scientific Co., Pittsburgh, PA), and the plates were developed in solvent 1 and visualized with resorcinol-HCl.
SerologicalAssays. The immune adherence (IA) assay was performed as described (1, 2, 4, 5) .
Qualitative and quantitative absorption tests were done according to procedures developed in our past work (1, 2, 4, 5, 6) . Glycolipid inhibition tests were performed as described in (7) . Diluted AH serum was mixed with 50 /~g of the acidic glycolipid fraction; the mixture was incubated for 30 min at room temperature and 30 min on ice and assayed for residual AH antibody. Purified gangliosides and SK-MEL-13 ganglioside fractions were tested in the same manner. Fig. 1 illustrates the reaction of AH serum with AH melanoma cells (SK-MEL-13) and three other melanoma cell lines. Tests with these and other cell lines showed that cells reacting with AH serum in direct tests absorbed the reactivity of AH serum for autologous SK-MEL-13 cells, whereas direct test-negative cells did not absorb autologous AH reactivity. One of the AH + cell lines, SK-MEL-31, showed higher reactivity with AH sera than did autologous SK-MEL-13 melanoma cells (Fig. 1) . Although this could have been caused by contaminating antibodies in AH sera, this proved not to be the case; preabsorption of AH sera with skin fibroblasts from the same donor as SK-MEL-31 did not lower reactivity for SK-MEL-31, and quantitative absorption tests indicated that SK-MEL-31 had > 10 times more AH antigen than AH melanoma. Because of this higher sensitivity to AH antibody, SK-MEL-31, rather than AH melanoma, was used as the target cell in subsequent absorption and inhibition tests. Biochemical Characterization of AH Antigen. The fact that AH antigenicity was not destroyed by trypsin, Pronase, formaldehyde (0.33%), or heating (100°C for 5 min) suggested that AH antigen might be a glycolipid. Consequently, neutral and acidic glycolipids were isolated from AH + SK-MEL-13 cells and tested for AH inhibitory activity. Acidic glycolipids were inhibitory, whereas neutral glycolipids had no detectable effect. The acidic glycolipid fraction from a series of AH + and AH-cells and tissues was subsequently tested (Table I) . Fractions from AH + sources were inhibitory, whereas fractions from AH-sources were not inhibitory. Partial purification of AH antibody-reactive ganglioside from SK-MEL-13 cells was carried out by Florisil, DEAE-Sephadex, and Iatrobead chromatography. Fig. 2 A shows the pattern of gangliosides eluted from the Iatrobead column. GM3 (fractions 86-98) and GD3 (fractions 99-122) are the major gangliosides of SK-MEL-13, as they were found to be in other melanomas (7) . Appreciable amounts of GM2 (fractions 99-107) and a number of minor components were also observed. Testing representative ganglioside fractions for AH reactivity showed that only one series of fractions (140-150) was active in inhibition tests. This corresponded to a minor component that co-migrated with GD2 in thin layer chromatograms (Fig. 2 B) . Because of the low yield of this ganglioside, a complete structural analysis was not possible.
Results

Reactivity of AH Serum with Autologous and Allogeneic Melanoma Cell Lines.
AH Phenotype of Normal and Malignant Human Cells.
Inhibition Tests with Purified Gangliosides. GM4, GM3, GM2, GM], GD3, GD2, aDla, GDlb,
and Gwlb were tested for AH inhibitory capacity (Fig. 3) . Only GDz was found to be inhibitory. Further inhibition tests showed that 1/~g of Gm or fraction 140-150 from SK-MEL-13 was sufficient for a 50% reduction in AH serum reactivity. ). Three other gangliosides (GM4, GDIb, and G'rlb) were also tested and found to be noninhibitory.
Discussion
Three classes of antigens have been distinguished in our analysis of the specificity of antibodies found in patients with melanoma (3). Antigens referred to as class 1 antigens show an absolute restriction to autologous melanoma cells, not being detected on any other malignant or normal cell type. Class 2 antigens, such as the AH antigen, are expressed by allogeneic as well as autologous melanoma and can be found on a limited range of normal cell types and other malignancies. Class 3 antigens are widely distributed on normal and malignant cells.
From the pattern of cellular distribution, AH antigen has the characteristics of a differentiation antigen of cells of neuroectodermal origin. This also seems to be the case for GD2, which was originally identified as a minor ganglioside in neural tissue (9, 10) . GD2 represents 8% of the total ganglioside content in adult grey matter (9) and 2% in human spinal cord (11) . The fact that AH antigen was detected initially by an autologous antibody indicates that this cell surface component can be autoantigenic. AH antibody belongs to the IgM class and is preferentially reactive at 4°C; in this respect it resembles other autoantibodies reactive with glycoconjugates, e.g., I, i (12), Pr (13, 14) , Gd (15), lacto-N-neotetraose (16) , and P blood group (17) . The stimulus for the production of AH antibody is unclear, particularly because AH antibody has also been detected in normal individuals (4) and astrocytoma patients (2).
Irie (18) and Gupta et al. (19) detected a cell surface antigen designated OFA or OFA-1 that has features in common with AH. However, OFA-1 has been reported to be absent from adult brain and present on fibroblasts, the converse of AH distribution. To clarify the relation between OFA-1 and AH, we have recently exchanged reagents with Dr. R. Irie. The two antigens appear to be related serologically, because OFA typing antibody reacted with AH + cells but not with AH-cells in a panel of 42 cell types. This finding was surprising, as OFA-1 has been reported to be C/M insoluble (19) and relatively unstable at 4°C (20) .
We recently reported (7) that another ganglioside, Gin, is a prominent glycolipid in melanoma, in contrast to other cell types. As GD2 is derived from the addition of GalNAc to Gin, it will be interesting to determine whether there is an inverse relationship between Gm and Go2 levels in melanomas and whether there is a difference in the specific transferase catalyzing Gm biosynthesis in AH + and AHmelanomas. An additional point has to do with the protective effect of antibody directed against AH/GD2 in patients with AH + melanoma, a possibility that is raised by the unexpected favorable course of the initial melanoma patient with AH antibody. AH ganglioside appears to be weakly immunogenic, as indicated by the low frequency of antibody in melanoma patients and normal individuals. Moreover, vaccination of melanoma patients with AH + melanoma cells did not elicit AH antibody, despite the inclusion of adjuvants such as BCG and C. parvum in the vaccine (21) . The weak immunogenicity of AH may be the result of several factors: (a) its presence in brain and other neuroectodermally derived tissues (leading to variable degrees of tolerance), (b) the low levels of AH ganglioside in melanoma cells, and (c) the recognized difficulty of raising antibody to gangliosides (22) . Use of Goz or the oligosaccharide derived from GD2 coupled to an immunogenic carrier provides another approach to increasing the immune response to AH antigen in melanoma patients.
Summary
AH antigen,initially defined by an antibody present in a melanoma patient, is a cell surface antigen found on ~65% of melanoma cell lines. Absorption analysis indicates that AH is a differentiation antigen marking normal and malignant cells of neuroectodermal origin. The AH determinant has been found to be related to GD2
